



FOR IMMEDIATE RELEASE

Rheonix, Inc. to Present Preclinical Data on Rheonix CARD™ Technology at AACC Annual Meeting

Ithaca, NY — July 22, 2010 — [Rheonix, Inc.](#) today announced that data demonstrating the utility of the [Rheonix CARD™ \(Chemistry And Reagent Device\) system](#) for human *in vitro* diagnostic purposes will be presented in poster sessions at the [American Association for Clinical Chemistry \(AACC\) Annual Meeting](#) being held in Anaheim, CA, July 25-29, 2010. Rheonix will also exhibit at the **Clinical Lab Expo, Booth #1432**.

The Rheonix CARD™ system is designed to meet the need for simple instrumentation that can perform a broad range of new or existing molecular diagnostic assays. Rheonix technology incorporates disposable microfluidic chip technology and a scalable automated platform to analyze single or multiple clinical raw samples, providing multiplexed endpoint analysis for a wide breadth of diagnostic applications.

Rheonix Presentations at AACC:

Wednesday, July 28, 2:00 PM - 4:30 PM Pacific Time

- Session 14, Presentation number D-09, “Fully Integrated, Automatic, and Rapid Molecular Detection and Identification of 20 Clinically Relevant HPV types using the CARD™ Platform”
- Session 14, Presentation number D-10, “CARD™ Technology for Rapid and Automatic Determination of SNP Profile for Pharmacogenomics”

Thursday, July 29, 9:00 AM - 12:00 PM Pacific Time

- Session 20, Presentation number E-05, “Rapid Molecular Detection of Sexually Transmitted Infections using a fully automated, microfluidic CARD™”

About the Rheonix CARD™ System

The Rheonix CARD™ (Chemistry And Reagent Device) system allows sophisticated molecular and/or immunologic assays to be integrated into a simple, modular platform with unprecedented raw sample preparation capabilities and broad, multiplex analysis applications. This technology is extremely versatile and outperforms its labor-intensive “bench-top” counterparts. Disposable Rheonix CARD technology can be customized for

immunoassay, pathogen identification, gene sequence detection, cell based assays and other molecular diagnostic applications. Rheonix CARD system advantages include:

- Virtually no hands-on effort, resulting in significantly reduced labor costs
- Reduced sample volumes and reagent volumes, saving time and money
- Performance of sophisticated assays through a series of programmable, automatic steps
- Integrated biosensors, which enable a highly-sensitive assay with digital readout of results on the completely disposable microfluidic Rheonix CARD technology
- Low-cost, scalable and reproducible manufacturing capabilities

To learn more about the Rheonix CARD system and its applications, please visit www.rheonix.com.

About Rheonix, Inc.

Rheonix has created a powerful microfluidic platform for the evolving molecular diagnostics industry. This system incorporates low-cost disposable Rheonix CARD™ technology to analyze single or multiple clinical raw samples. The Rheonix CARD system provides multiplexed endpoint analysis and can be rapidly customized for a wide breadth of diagnostic applications. www.rheonix.com

###

Contacts:

Rheonix, Inc.:
Tony Eisenhut, President/CEO
607-257-1242, ext. 160

Media Contact:
Douglas MacDougall or Jacqui Miller
MacDougall Biomedical Communications
781-235-3060